title: Fas expression in lung metastasis from osteosarcoma patients.
abstract: The authors' animal studies have shown that the metastatic potential of osteosarcoma (OS) cells correlates inversely with Fas expression-that is, Fas-negative cells metastasize but Fas-positive cells do not. One reason for this in the context of OS lung metastases may be that Fas-positive cells are eliminated by engagement with the Fas ligand (FasL) constitutively expressed on the surface of pneumocytes, whereas Fas-negative tumor cells are not. The purpose of this study was to determine the status of Fas expression in OS lung metastases from patients. Specifically, archived paraffin-embedded specimens of lung metastases from 38 patients with OS were analyzed by immunohistochemistry. Lung nodules from 23 of the 38 patients (60%) were Fas negative, those from 12 patients (32%) were weakly positive, and that from only 1 patient (3%) was strongly positive. Findings in the samples from the remaining two patients (5%) could not be interpreted because of extensive necrosis. Most patients with the weakly positive tumors and the single patient with the strongly positive tumor received chemotherapy prior to lung resection. There was a significant correlation between Fas expression and the administration of preoperative salvage chemotherapy (P = 0.0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas.
authors.affiliation: Division of Pediatrics, Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, and Division of Pediatrics Hematology/Oncology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Gordon
authors.forename: Carola A S
authors.initials: CA
authors.lastname: Arndt
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Hawkins
authors.forename: Debra K
authors.initials: DK
authors.lastname: Doherty
authors.forename: Carrie Y
authors.initials: CY
authors.lastname: Inwards
authors.forename: Mark F
authors.initials: MF
authors.lastname: Munsell
authors.forename: John
authors.initials: J
authors.lastname: Stewart
authors.forename: Nadezhda V
authors.initials: NV
authors.lastname: Koshkina
authors.forename: Eugenie S
authors.initials: ES
authors.lastname: Kleinerman
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003713:Dendritic Cells / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000556:secondary*; D008727:Methotrexate / Q000008:administration & dosage; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000188:drug therapy / Q000378:metabolism* / Q000556:secondary*; D016612:Paraffin Embedding; D011300:Preoperative Care; D019014:fas Receptor / Q000378:metabolism*
chemical_list: D019014:fas Receptor; D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate